The health benefits of the (n-3) PUFA EPA and DHA have created a demand for fish and fish oil, the main sources of these PUFA. Production animals, such as poultry, are potential alternate and sustainable sources of EPA and DHA, provided these fatty acids can be synthesized from plant-derived a-linolenic acid [ALA,]. Because elongases are potential control points in the conversion of ALA to DHA in rats, we examined the chicken elongases, ELOVL2 and ELOVL5, which had not been characterized. ELOVL2 activity was limited to C20-22 PUFA substrates and the major product of ELOVL2 metabolism of EPA was 24:5(n-3). This indicates that ELOVL2 can sequentially elongate EPA to docosapentaenoic acid [DPA, 22:5(n-3)] and then onto 24:5(n-3). ELOVL5 selectivity was broader with elongation of C18-22 PUFA substrates. The ability of chicken ELOVL5 to efficiently synthesize 24:5(n-3) is unique compared with ELOVL5 enzymes from other species. The expression of ELOVL5 was higher than ELOVL2 in livers of broiler chickens and their expression did not change when dietary ALA was increased from 0.6 to 1.3% of dietary energy for 42 d. The expression of both genes was higher than previously seen in rats. The chicken elongase enzymes are unlike those of any species studied to date, because both ELOVL2 and ELOVL5 have the ability to efficiently elongate DPA. In addition, the relative abundance of ELOVL2 and ELOVL5 in the liver suggests that chickens may be able to metabolize more DPA through to 24:5(n-3), the precursor of DHA, compared with other species such as rats. J. Nutr.
Introduction
The health benefits of EPA and DHA have driven human use to an extent that there are concerns that fish and fish oil cannot meet this demand. A sustainable alternative could be the use of production animals as a source of EPA and DHA, provided that these fatty acids could be synthesized from plant-derived a-linolenic acid [ALA, 6 18:3(n-3)]. The conversion of ALA to EPA and DHA in animals requires progressive desaturation and elongation. The reaction catalyzed by D6 desaturase has been shown to be rate limiting for the conversion of ALA to EPA in rodents and humans (1) (2) (3) . However, 2 elongase enzymes are also required for the synthesis of DHA from ALA and the focus on D6 desaturase has detracted from the examination of the potential for the elongation reactions to function as control points.
Human and rat elongase-5 (ELOVL5) elongates C18 and C20 PUFA (4-6) and human, mouse, and rat elongase-2 (ELOVL2) elongates C20 and C22 PUFA (6, 7) . We have shown that rat ELOVL2 catalyzes elongation of EPA to docosapentaenoic acid [DPA, 22:5(n-3)] and then elongation of DPA to 24:5(n-3), with apparent saturation of the second reaction without saturation of the first reaction; this may explain the increase in DPA but not DHA after certain intakes of ALA have been exceeded (6) . Thus, our previous study in rats highlighted that ELOVL2 is essential for DHA synthesis and it is another potential control point for the conversion of ALA to DHA.
Although the effect of dietary ALA on EPA, DPA, and DHA content in chicken breast and thigh meat has been thoroughly investigated, there is considerable variability in findings with regard to DHA synthesis (8) (9) (10) (11) (12) . Chickens could be a useful population source of EPA and DHA, because chicken meat is consumed in large quantities relative to other meat in Australia and worldwide (13) . However, understanding how ALA conversion to EPA, and in particular DHA, might be increased requires knowledge of the status of the chicken elongase enzymes. Although putative ELOVL2 and ELOVL5 genes have been identified in the chicken genome, these have not been functionally characterized.
This study reports the substrate specificities and dose response curves of the chicken elongases, ELOVL2 and ELOVL5, using a yeast heterologous expression system.
Materials and Methods
Cloning the chicken ELOVL2 and ELOVL5 cDNA. Total RNA was extracted from the liver of Australian Cobb 500 chickens with the RNeasy kit (Qiagen). RT-PCR amplifications of ELOVL2 and ELOVL5 were performed using the primers in Supplemental Table 1 and were cloned into the expression vector pYES2 (Invitrogen) as previously described (6) .
Heterologous expression of the chicken ELOVL2 and ELOVL5 in Saccharomyces cerevisiae. The pYES2-ELOVL2 and pYES2-ELOVL5 constructs were used to transform the S. cerevisiae strain INVSc1 for the production of recombinant protein. Transformation, selection, and maintenance of S. cerevisiae were performed as previously described (6) . Recombinant yeast expressing ELOVL2 or ELOVL5 were supplemented with 100 mmol/L of the following PUFA substrates: 18:4 (n-3) [stearidonic acid (SDA)], 18:3(n-6) (g-linolenic acid), 20:5(n-3) (EPA), 20:4(n-6) (arachidonic acid), 22:5(n-3) (DPA), or 22:4(n-6). Dose response curves were generated by supplementing with 100-400 mmol/L of EPA or DPA. Data are expressed as the mean 6 SD of incubations from 3 independent samples.
Animals, diets, and study design. This study was approved by the Animal Ethics Committees of the Department of Primary Industries South Australia (#16/11) and the University of Adelaide (S-2011-171). One hundred and sixty day-old male Cobb 500 broilers were obtained from the Baiada Poultry hatchery and randomly allocated to 16 pens (10 birds/pen). Pens were randomly allocated in blocks to 1 of 2 experimental diets (8 pens/treatment). The 42-d study was conducted at the Pig and Poultry Production Institute (Roseworthy Campus, University of Adelaide, SA, Australia). A light cycle of 23 h light and 1 h dark was used for the first 4 d and then 12 h light and 12 h dark was maintained until the end of the study. The environmental conditions were checked at least daily and the chickens were observed twice daily. All experimental diets were based on a reduced-fat basal diet with 3% added tallow or canola oil, a rich source of ALA (Ridley Agriproducts) (Supplemental Table 2 ). All diets were matched for energy. Two-phase feeding was used. The first feed was a starter/grower diet (1.8 kg/bird) and the second diet was a finisher/withdrawal diet (consumed ad libitum until the end of the trial). Although the basal diet contained canola meal that supplied ''basal'' ALA to both groups, this was done to mimic a commercial diet.
Sample collection. At 42 d of age, 2 birds from each pen (n = 16/ treatment) were individually weighed and killed by cervical dislocation. A section of liver was collected and stored at 220°C until fatty acid analysis was performed on tissue from 1 bird/pen (n = 8). Small sections of liver were collected and stored in RNAlater (Ambion) at 280°C until qRT-PCR analysis was performed.
Fatty acid analysis. Total lipid was extracted from yeast, feed, and liver tissue using chloroform:methanol (2:1, v:v). Approximately 1 g of ground feed and 300 mg of tissue were used for extraction and the exact weights were recorded. The liver phospholipid fraction was separated from the remaining lipid classes by TLC using a mobile phase of petroleum spirit:acetone (3:1, v:v). Yeast total lipid, feed total lipid, or liver phospholipids were methylated in 1% sulfuric acid in methanol (v:v) at 70°C for 3 h to prepare FAME. FAME were then extracted and analyzed by GC as previously described (14) . The identity of each fatty acid peak in the chromatogram was ascertained by comparing its retention time to authentic lipid standards (NuChek Prep and Larodan Fine Chemicals). The identities of 20:4(n-3) and 22:4(n-3) were previously confirmed by GC-MS (14) . FAME were quantified using GC Chemstation software (Agilent Technologies). The amount of each fatty acid was expressed either in mol fatty acid/g yeast or as a percentage of the total amount of all fatty acids. The internal FFA standard 17:0 was added prior to lipid extraction and used to quantify the amount of each yeast endogenous fatty acid. The proportion of substrate fatty acid converted to longer chain fatty acid product(s) was calculated as [product(s)/(product(s) + substrate)] 3 100. To calculate the amount of each fatty acid as a percentage of the total amount of all fatty acids, the peak area for an individual fatty acid was expressed as a percentage of the total peak area for all fatty acids. All solvents contained 0.005% (wt:v) butylated hydroxyanisole as antioxidant.
Chicken ELOVL2 and ELOVL5 expression levels. Three Cobb 500 broilers from each of the experimental diets were randomly selected for analysis of liver ELOVL2 and ELOVL5 expression levels. The liver tissue was stored in RNAlater at 280°C until RNA isolation was performed. Total RNA was extracted, cDNA synthesized, and qRT-PCR performed as previously described (6) . The QuantiTect Primer Assays used were ELOVL2 (Gg_Elovl2_1_SG, QT00640605) and ELOVL5 (Gg_Elovl5_2_SG, QT01494052). The ELOVL2 or ELOVL5 PCR products were used to make 10-fold serial dilutions from 10 5 copies down to 10 copies. The PCR product standard curve equations were used to calculate the absolute copy number of ELOVL2 and ELOVL5 in chicken liver. Data are expressed as the mean 6 SEM (n = 3) and each amplification was performed in duplicate.
Statistical analysis. Data obtained from expression of ELOVL2 and ELOVL5 in S. cerevisiae were analyzed by 1-way ANOVA with TukeyÕs post hoc test. The effect of diet on ELOVL2 and ELOVL5 expression was checked for equal variance and analyzed by an unpaired t test (2-tailed) and the difference in ELOVL2 and ELOVL5 expression within birds was analyzed by a paired t test (2-tailed). Liver phospholipid (n-3) PUFA data were analyzed by 2-way ANOVA with a Bonferroni post-hoc test. All analyses were performed using Graphpad Prism version 5.03 for Windows (Graphpad Software). Significance was set at P < 0.05.
Results
Sequence analysis of the chicken ELOVL2 and ELOVL5. Amplification of the 894-bp ELOVL2 open reading frame and subsequent alignment with the putative chicken ELOVL2 sequence in GenBank (NM_001197308) revealed 3 nucleotide differences. The ELOVL2 sequence was deposited in GenBank as accession number JX052267. The predicted ELOVL2 protein of 297 amino acids was identical to NP_001184237. Amplification of the 888-bp ELOVL5 open reading frame and subsequent alignment with the putative chicken ELOVL5 sequence in GenBank (NM_001199197) revealed the 2 sequences were identical.
Comparison of chicken ELOVL2 and ELOVL5 substrate specificities. Recombinant S. cerevisiae cells expressing ELOVL2 or ELOVL5 were cultured in the presence of 100 mmol/L of various C18-22 PUFA to determine substrate specificities of the elongases. ELOVL5 had a broad substrate specificity with elongase activity with C18, C20, and C22 PUFA, although there was less activity with the C22 PUFA (Fig. 1A) . In contrast, ELOVL2 was active with C20 and C22 PUFA but not C18 PUFA substrates (Fig. 1B) . ELOVL2 had a clear preference for (n-3) PUFA over (n-6) PUFA substrates. By contrast, ELOVL5 had similar activity with (n-3) PUFA and (n-6) PUFA substrates for the C18 and C20 PUFA, but there was an (n-3) PUFA over (n-6) PUFA preference for the C22 PUFA.
Examination of product/substrate relationships for ELOVL2 and ELOVL5. The substrate specificity results indicate that ELOVL2 and ELOVL5 both have the capacity to convert EPA to DPA and then further convert endogenously generated DPA to 24:5(n-3). To assess the relative efficiencies of the 2 enzymes for these reactions, the EPA and DPA dose responses were examined.
For ELOVL5, there was a proportional increase in DPA synthesis with increasing concentrations of EPA, but 24:5(n-3) synthesized from endogenous DPA remained a minor product and did not increase proportionally ( Fig. 2A) . In the presence of exogenous DPA, 24:5(n-3) also remained a minor product and did not increase proportionally (Fig. 2B) . By contrast, 24:5(n-3) was the major product of ELOVL2 metabolism of EPA at most concentrations of EPA; DPA remained a minor product, presumably because it was converted efficiently to 24:5(n-3) (Fig. 2C) . In the presence of exogenous DPA, there was a proportional increase in 24:5(n-3) up to 200 mmol/L DPA and then apparent saturation at higher DPA concentrations (Fig.  2D) .
Effect of dietary ALA on elongase expression and elongase products in the liver of broilers. ELOVL5 was present at higher levels than ELOVL2 in liver (P < 0.05) (Fig. 3) . The expression of either ELOVL2 or ELOVL5 was not altered by the increase in dietary ALA (Fig. 3) .
DHA was the most abundant (n-3) long-chain PUFA (LCPUFA) in liver phospholipids. Chickens fed canola oil had an increase in liver phospholipid DHA (P < 0.05) and total (n-3) LCPUFA (P < 0.0001) content compared with those fed the standard tallow diet (Fig. 4) .
Discussion
The effect of dietary ALA on broiler breast and thigh (n-3) LCPUFA has been investigated in many studies (8) (9) (10) (11) (12) 15) . Whereas an increase in meat EPA and DHA has been seen in some studies (8, 9, 12) , others observed an increase in EPA but not DHA (11) , an increase in DHA but not EPA (10), or no increase in either EPA or DHA (15) . The effect of dietary ALA on the (n-3) LCPUFA content in eggs is more consistent between studies, with eggs being enriched with DHA to a much greater extent than with EPA (16) . The liver is the main site for the jn.nutrition.org synthesis of fatty acids, which are then deposited into eggs and muscle, although breast and thigh probably have some fatty acid synthesis capabilities. Given the economic importance of chicken products and the variable response in tissue EPA and DHA after modifying dietary (n-3) intake, it is surprising that the enzymes involved in the metabolism of EPA and DHA have never been investigated, to our knowledge. Therefore, we examined the elongase enzymes involved in synthesis of EPA and DHA in liver.
Our study is the first to our knowledge to clone and functionally characterize the broiler elongase enzymes, ELOVL2 and ELOVL5. The chicken ELOVL2 activity was limited to C20-22 PUFA substrates, unlike the rat and mouse ELOVL2, which also demonstrated some activity toward C18 PUFA (6,7). In contrast, the chicken ELOVL5 had a broader substrate specificity compared with the rat and human ELOVL5, because it elongated C18-22 PUFA (5,6). The rat and human ELOVL5 do not elongate C22 PUFA (5, 6) . It is unclear if this extra C22 PUFA elongation function that the chicken ELOVL5 exhibits is specific to chickens or extends to all birds. Currently, there are no other functionally characterized elongase enzymes from birds.
Dose-response curves were used to examine the product/ substrate relationships for ELOVL2 and ELOVL5. The major product of ELOVL2 metabolism of EPA was 24:5(n-3), which requires conversion of EPA to DPA followed by further elongation of DPA to 24:5(n-3). When DPA was exogenously supplied, there was a proportional increase in 24:5(n-3) up to 200 mmol/L DPA and then apparent saturation of ELOVL2 at higher concentrations of DPA. These findings are similar to the rat ELOVL2 , which appeared to be saturated by DPA at concentrations not saturating for EPA (6) . The major product of ELOVL5 metabolism of EPA was DPA, although there was further elongation of both endogenous and exogenous DPA to 24:5(n-3). Synthesis of 24:5(n-3) has never been reported for ELOVL5 from a non-piscine species. The combined ability of both the chicken ELOVL2 and ELOVL5 to convert DPA to 24:5 (n-3) may enable chickens to synthesize more 24:5(n-3) and subsequently more DHA than other species such as rats and humans.
The copy numbers of liver ELOVL2 and ELOVL5 transcripts were 4.6-and 1.8-fold higher, respectively, than their counterparts in rats (6) . The expression of ELOVL2 and ELOVL5 in chicken liver was not affected by exchanging dietary tallow for canola oil, which increased ALA from 0.6 to 1.3% of dietary energy. With the canola oil diet, there was a significant increase in hepatic DHA but not EPA or DPA. This is in contrast to the effect in rats where an increase in dietary ALA from 0.2 to 2.9% energy resulted in a proportional increase in rat hepatic EPA and DPA, but not DHA; i.e., in rats, there appears to be an impediment in the conversion of DPA to DHA (17) . The effect of dietary ALA on DHA accumulation in chickens and rats may be different due to the combined greater efficiency of chicken ELOVL5 plus ELOVL2 for conversion of DPA to 24:5 (n-3) compared with rats. Rats rely solely on the activity of ELOVL2, which is expressed at low levels. However, there are other explanations such as increased b-oxidation of EPA and DPA in rat livers or increased transport from the liver to other tissues in rats compared with chickens.
This report has shown that the chicken elongase enzymes are unlike any species studied to date, because both the ELOVL2 and ELOVL5 can elongate DPA. Mammalian ELOVL5 enzymes are unable to elongate DPA (5,6) and most fish ELOVL5 enzymes have low or undetectable activity toward DPA (14, (18) (19) (20) (21) (22) (23) . The ELOVL5 enzymes of gilthead sea bream, zebrafish, cobia, and Atlantic bluefin tuna can convert DPA to 24:5(n-3) but with DPA conversion rates of 4.7-8.6% (18, 19, 22, 23) . These rates are much lower than that of the chicken ELOVL5, which elongates 20.4% of DPA. Although the DPA conversion rate is used here to compare across species, it must be noted that the concentration of substrate DPA and the length of incubation time varied between studies (18, 19, 22, 23) .
In mammals and most fish, the inability of ELOVL5 to elongate DPA indicates a dependency on ELOVL2 for synthesis of 24:5(n-3) and subsequent DHA synthesis. Prior to this study, Atlantic salmon and zebrafish were the only non-mammalian vertebrates with a functionally characterized ELOVL2 capable of converting DPA to 24:5(n-3) (18, 24) .
The rat has been used for many studies that have examined metabolism of dietary ALA. It is commonly stated that D6 desaturase is rate limiting for ALA metabolism to (n-3) LCPUFA. This is because the D6 desaturase product, SDA, is metabolized more efficiently than the D6 desaturase substrate, ALA, in rats and humans (2,3). However, both ALA and SDA increased tissue EPA but not DHA (2,3) and a review of SDA metabolism concluded that only dietary DHA can elevate tissue DHA (25) . Therefore, one cannot conclude that D6 desaturase is rate limiting for DHA synthesis. The accumulation of EPA and DPA, but not DHA, is a common finding (3, 17) . This is most likely a reflection of the low levels of expression of ELOVL2 and the inability of ELOVL5 to elongate DPA (6) . By contrast, the ability of the chicken ELOVL5 to elongate DPA and the relative increased abundance of ELOVL2 and ELOVL5 in chicken compared with rat liver suggest that chickens may be able to FIGURE 3 Comparison of the absolute number of ELOVL2 and ELOVL5 mRNA copies in chicken liver. Values are means 6 SEM, n = 3. *Different from ELOVL2, P , 0.05.
FIGURE 4
The effects of 3% dietary canola oil on liver phospholipid (n-3) PUFA in chickens. Values are means 6 SD, n = 8. Asterisks indicate that means differ: *P , 0.05, **P , 0.0001. ALA, a-linolenic acid, 18:3(n-3); DPA, docosapentaenoic acid, 22:5(n-3); LCPUFA, longchain PUFA. metabolize more DPA through to 24:5(n-3), the precursor of DHA, compared with rats. In support of this hypothesis, we confirmed previous observations in chickens that dietary ALA increases liver DHA (9, 10, 12) .
The comparison of the chicken (n-3) LCPUFA synthetic capabilities with those of rats suggests that the elongases are an important difference in the ability of chickens to synthesize DHA. The variability in breast and thigh DHA content after ALA feeding (8) (9) (10) (11) (12) 15 ) may be mainly a reflection of variability in transport from liver to muscle. Nevertheless, the importance of ELOVL2 expression and ELOVL5 DPA elongation activity could provide a target for breeding poultry that readily produce DHA from ALA. The consumer benefits may be more evident for egg production, where efficient DHA transport from liver to egg has been established (16) , rather than meat production. Whatever the outcome for edible chicken products, understanding liver synthesis of DHA is critical for improving chicken DHA content.
